ID   TERT_MOUSE              Reviewed;        1122 AA.
AC   O70372; O35432; Q9JK99;
DT   30-MAY-2000, integrated into UniProtKB/Swiss-Prot.
DT   01-AUG-1998, sequence version 1.
DT   18-JUN-2025, entry version 188.
DE   RecName: Full=Telomerase reverse transcriptase;
DE            EC=2.7.7.49;
DE   AltName: Full=Telomerase catalytic subunit;
GN   Name=Tert;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Mus; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, DEVELOPMENTAL STAGE, INDUCTION, AND
RP   TISSUE SPECIFICITY.
RX   PubMed=9582020; DOI=10.1038/sj.onc.1201933;
RA   Greenberg R.A., Allsopp R.C., Chin L., Morin G.B., DePinho R.A.;
RT   "Expression of mouse telomerase reverse transcriptase during development,
RT   differentiation and proliferation.";
RL   Oncogene 16:1723-1730(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND TISSUE SPECIFICITY.
RX   PubMed=9724727; DOI=10.1073/pnas.95.18.10471;
RA   Martin-Rivera L., Herrera E., Albar J.P., Blasco M.A.;
RT   "Expression of mouse telomerase catalytic subunit in embryos and adult
RT   tissues.";
RL   Proc. Natl. Acad. Sci. U.S.A. 95:10471-10476(1998).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 548-1122, AND TISSUE SPECIFICITY.
RX   PubMed=13679242; DOI=10.1016/s0024-3205(03)00670-2;
RA   Wong S.C., Ong L.L., Er C.P., Gao S., Yu H., So J.B.;
RT   "Cloning of rat telomerase catalytic subunit functional domains,
RT   reconstitution of telomerase activity and enzymatic profile of pig and
RT   chicken tissues.";
RL   Life Sci. 73:2749-2760(2003).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 550-616.
RA   Drissi R., Cleveland J.L.;
RT   "Partial sequence of Mus musculus telomerase catalytic subunit homolog.";
RL   Submitted (OCT-1997) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   INTERACTION WITH PIF1, AND FUNCTION.
RX   PubMed=17130244; DOI=10.1128/mcb.01866-06;
RA   Snow B.E., Mateyak M., Paderova J., Wakeham A., Iorio C., Zakian V.,
RA   Squire J., Harrington L.;
RT   "Murine Pif1 interacts with telomerase and is dispensable for telomere
RT   function in vivo.";
RL   Mol. Cell. Biol. 27:1017-1026(2007).
RN   [6]
RP   INTERACTION WITH GNL3L.
RX   PubMed=19487455; DOI=10.1083/jcb.200812121;
RA   Zhu Q., Meng L., Hsu J.K., Lin T., Teishima J., Tsai R.Y.;
RT   "GNL3L stabilizes the TRF1 complex and promotes mitotic transition.";
RL   J. Cell Biol. 185:827-839(2009).
RN   [7]
RP   INTERACTION WITH SMARCA4, AND FUNCTION.
RX   PubMed=19571879; DOI=10.1038/nature08137;
RA   Park J.I., Venteicher A.S., Hong J.Y., Choi J., Jun S., Shkreli M.,
RA   Chang W., Meng Z., Cheung P., Ji H., McLaughlin M., Veenstra T.D.,
RA   Nusse R., McCrea P.D., Artandi S.E.;
RT   "Telomerase modulates Wnt signalling by association with target gene
RT   chromatin.";
RL   Nature 460:66-72(2009).
CC   -!- FUNCTION: Telomerase is a ribonucleoprotein enzyme essential for the
CC       replication of chromosome termini in most eukaryotes. Active in
CC       progenitor and cancer cells. Inactive, or very low activity, in normal
CC       somatic cells. Catalytic component of the teleromerase holoenzyme
CC       complex whose main activity is the elongation of telomeres by acting as
CC       a reverse transcriptase that adds simple sequence repeats to chromosome
CC       ends by copying a template sequence within the RNA component of the
CC       enzyme. Catalyzes the RNA-dependent extension of 3'-chromosomal termini
CC       with the 6-nucleotide telomeric repeat unit, 5'-TTAGGG-3'. The
CC       catalytic cycle involves primer binding, primer extension and release
CC       of product once the template boundary has been reached or nascent
CC       product translocation followed by further extension. More active on
CC       substrates containing 2 or 3 telomeric repeats. Telomerase activity is
CC       regulated by a number of factors including telomerase complex-
CC       associated proteins, chaperones and polypeptide modifiers. Modulates
CC       Wnt signaling. Plays important roles in aging and antiapoptosis (By
CC       similarity). {ECO:0000250, ECO:0000269|PubMed:17130244,
CC       ECO:0000269|PubMed:19571879, ECO:0000269|PubMed:9582020}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=DNA(n) + a 2'-deoxyribonucleoside 5'-triphosphate = DNA(n+1) +
CC         diphosphate; Xref=Rhea:RHEA:22508, Rhea:RHEA-COMP:17339, Rhea:RHEA-
CC         COMP:17340, ChEBI:CHEBI:33019, ChEBI:CHEBI:61560, ChEBI:CHEBI:173112;
CC         EC=2.7.7.49; Evidence={ECO:0000255|PROSITE-ProRule:PRU00405};
CC   -!- SUBUNIT: Catalytic component of the telomerase holoenzyme complex
CC       composed of one molecule of TERT, one molecule of WRAP53/TCAB1, two
CC       molecules of H/ACA ribonucleoprotein complex subunits DKC1, NOP10, NHP2
CC       and GAR1, and a telomerase RNA template component (TERC). The
CC       telomerase holoenzyme complex is associated with TEP1, SMG6/EST1A and
CC       POT1. The molecular chaperone HSP90/P23 complex is required for correct
CC       assembly and stabilization of the active telomerase. Interacts directly
CC       with HSP90A and PTGES3. Interacts with HSPA1A; the interaction occurs
CC       in the absence of TERC and dissociates once the complex has formed.
CC       Interacts with RAN; the interaction promotes nuclear export of TERT.
CC       Interacts with XPO1. Interacts with PTPN11; the interaction retains
CC       TERT in the nucleus. Interacts with NCL (via RRM1 and C-terminal
CC       RRM4/Arg/Gly-rich domains); the interaction is important for nucleolar
CC       localization of TERT (By similarity). Interacts with SMARCA4 (via the
CC       bromodomain); the interaction regulates Wnt-mediated signaling
CC       (PubMed:19571879). Interacts with MCRS1 (isoform MCRS2); the
CC       interaction inhibits in vitro telomerase activity (By similarity).
CC       Interacts with PIF1; the interaction has no effect on the elongation
CC       activity of TERT (PubMed:17130244). Interacts with PML; the interaction
CC       recruits TERT to PML bodies and inhibits telomerase activity (By
CC       similarity). Interacts with GNL3L (PubMed:19487455). Interacts with
CC       isoform 1 and isoform 2 of NVL (By similarity). Interacts with DHX36
CC       (By similarity). Interacts with ATF7 (By similarity).
CC       {ECO:0000250|UniProtKB:O14746, ECO:0000269|PubMed:17130244,
CC       ECO:0000269|PubMed:19487455, ECO:0000269|PubMed:19571879}.
CC   -!- INTERACTION:
CC       O70372; Q3TKT4: Smarca4; NbExp=2; IntAct=EBI-9662790, EBI-1210244;
CC   -!- SUBCELLULAR LOCATION: Nucleus, nucleolus
CC       {ECO:0000250|UniProtKB:O14746}. Nucleus, nucleoplasm {ECO:0000250}.
CC       Nucleus. Chromosome, telomere. Cytoplasm {ECO:0000250}. Nucleus, PML
CC       body {ECO:0000250}. Note=Shuttling between nuclear and cytoplasm
CC       depends on cell cycle, phosphorylation states, transformation and DNA
CC       damage. Diffuse localization in the nucleoplasm. Enriched in nucleoli
CC       of certain cell types. Translocated to the cytoplasm via nuclear pores
CC       in a CRM1/RAN-dependent manner involving oxidative stress-mediated
CC       phosphorylation at Tyr-697. Dephosphorylation at this site by SHP2
CC       retains TERT in the nucleus. Translocated to the nucleus by
CC       phosphorylation by AKT (By similarity). {ECO:0000250}.
CC   -!- TISSUE SPECIFICITY: High activity in intestine, liver and testis,
CC       moderate in lung, very low in muscle, heart and brain.
CC       {ECO:0000269|PubMed:13679242, ECO:0000269|PubMed:9582020,
CC       ECO:0000269|PubMed:9724727}.
CC   -!- DEVELOPMENTAL STAGE: Highest levels in midgestational stages, 9.5 dpc
CC       to 15.5 dpc. {ECO:0000269|PubMed:9582020}.
CC   -!- DOMAIN: The primer grip sequence in the RT domain is required for
CC       telomerase activity and for stable association with short telomeric
CC       primers. {ECO:0000250}.
CC   -!- DOMAIN: The RNA-interacting domain 1 (RD1)/N-terminal extension (NTE)
CC       is required for interaction with the pseudoknot-template domain of each
CC       of TERC dimers. It contains anchor sites that bind primer nucleotides
CC       upstream of the RNA-DNA hybrid and is thus an essential determinant of
CC       repeat addition processivity (By similarity). {ECO:0000250}.
CC   -!- DOMAIN: The RNA-interacting domain 2 (RD2) is essential for both
CC       interaction with the CR4-CR5 domain of TERC and for DNA synthesis.
CC       {ECO:0000250}.
CC   -!- PTM: Phosphorylation at Tyr-697 under oxidative stress leads to
CC       translocation of TERT to the cytoplasm and reduces its antiapoptotic
CC       activity. Dephosphorylated by SHP2/PTPN11 leading to nuclear retention.
CC       Phosphorylation by the AKT pathway promotes nuclear location.
CC       Phosphorylation at the G2/M phase at Ser-447 by DYRK2 promotes
CC       ubiquitination by the EDVP complex and degradation (By similarity).
CC       {ECO:0000250}.
CC   -!- PTM: Ubiquitinated by the EDVP complex, a E3 ligase complex following
CC       phosphorylation at Ser-447 by DYRK2. Ubiquitinated leads to proteasomal
CC       degradation (By similarity). {ECO:0000250}.
CC   -!- SIMILARITY: Belongs to the reverse transcriptase family. Telomerase
CC       subfamily. {ECO:0000305}.
CC   -!- CAUTION: Was originally thought to originate from rat.
CC       {ECO:0000305|PubMed:13679242}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF051911; AAC09323.1; -; mRNA.
DR   EMBL; AF073311; AAC34821.1; -; mRNA.
DR   EMBL; AF247818; AAF62177.1; -; mRNA.
DR   EMBL; AF029235; AAB84200.1; -; mRNA.
DR   CCDS; CCDS26633.1; -.
DR   RefSeq; NP_033380.1; NM_009354.2.
DR   AlphaFoldDB; O70372; -.
DR   SMR; O70372; -.
DR   BioGRID; 204118; 2.
DR   ComplexPortal; CPX-1124; Telomerase holoenzyme complex.
DR   ComplexPortal; CPX-19; Telomerase catalytic core complex.
DR   ComplexPortal; CPX-22; TERT-RMRP complex.
DR   DIP; DIP-60451N; -.
DR   FunCoup; O70372; 231.
DR   IntAct; O70372; 3.
DR   STRING; 10090.ENSMUSP00000022104; -.
DR   GlyGen; O70372; 1 site.
DR   iPTMnet; O70372; -.
DR   PhosphoSitePlus; O70372; -.
DR   PaxDb; 10090-ENSMUSP00000022104; -.
DR   Antibodypedia; 8998; 984 antibodies from 41 providers.
DR   DNASU; 21752; -.
DR   Ensembl; ENSMUST00000022104.9; ENSMUSP00000022104.8; ENSMUSG00000021611.10.
DR   GeneID; 21752; -.
DR   KEGG; mmu:21752; -.
DR   UCSC; uc007rdq.1; mouse.
DR   AGR; MGI:1202709; -.
DR   CTD; 7015; -.
DR   MGI; MGI:1202709; Tert.
DR   VEuPathDB; HostDB:ENSMUSG00000021611; -.
DR   eggNOG; KOG1005; Eukaryota.
DR   GeneTree; ENSGT00390000018531; -.
DR   HOGENOM; CLU_001996_2_0_1; -.
DR   InParanoid; O70372; -.
DR   OMA; SYKAVQW; -.
DR   OrthoDB; 289721at2759; -.
DR   PhylomeDB; O70372; -.
DR   Reactome; R-MMU-171319; Telomere Extension By Telomerase.
DR   Reactome; R-MMU-201722; Formation of the beta-catenin:TCF transactivating complex.
DR   BioGRID-ORCS; 21752; 6 hits in 82 CRISPR screens.
DR   ChiTaRS; Tert; mouse.
DR   PRO; PR:O70372; -.
DR   Proteomes; UP000000589; Chromosome 13.
DR   RNAct; O70372; protein.
DR   Bgee; ENSMUSG00000021611; Expressed in paneth cell and 137 other cell types or tissues.
DR   ExpressionAtlas; O70372; baseline and differential.
DR   GO; GO:0000781; C:chromosome, telomeric region; IEA:UniProtKB-SubCell.
DR   GO; GO:0005737; C:cytoplasm; IDA:MGI.
DR   GO; GO:0005829; C:cytosol; IEA:Ensembl.
DR   GO; GO:0042645; C:mitochondrial nucleoid; IEA:Ensembl.
DR   GO; GO:0005739; C:mitochondrion; IDA:BHF-UCL.
DR   GO; GO:0016607; C:nuclear speck; IEA:Ensembl.
DR   GO; GO:0005730; C:nucleolus; ISS:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:MGI.
DR   GO; GO:0016605; C:PML body; IEA:UniProtKB-SubCell.
DR   GO; GO:0000333; C:telomerase catalytic core complex; IMP:BHF-UCL.
DR   GO; GO:0005697; C:telomerase holoenzyme complex; ISS:UniProtKB.
DR   GO; GO:1990572; C:TERT-RMRP complex; ISS:ComplexPortal.
DR   GO; GO:0003677; F:DNA binding; IEA:UniProtKB-KW.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0042803; F:protein homodimerization activity; IEA:Ensembl.
DR   GO; GO:0051087; F:protein-folding chaperone binding; IEA:Ensembl.
DR   GO; GO:0003723; F:RNA binding; IPI:BHF-UCL.
DR   GO; GO:0003968; F:RNA-directed RNA polymerase activity; IEA:Ensembl.
DR   GO; GO:0003720; F:telomerase activity; IDA:MGI.
DR   GO; GO:0070034; F:telomerase RNA binding; IPI:BHF-UCL.
DR   GO; GO:0098680; F:template-free RNA nucleotidyltransferase; IEA:Ensembl.
DR   GO; GO:0001223; F:transcription coactivator binding; IPI:BHF-UCL.
DR   GO; GO:0000049; F:tRNA binding; IEA:Ensembl.
DR   GO; GO:0071456; P:cellular response to hypoxia; IEA:Ensembl.
DR   GO; GO:0022616; P:DNA strand elongation; IEA:Ensembl.
DR   GO; GO:0070200; P:establishment of protein localization to telomere; IEA:Ensembl.
DR   GO; GO:0007507; P:heart development; IEA:Ensembl.
DR   GO; GO:0007005; P:mitochondrion organization; IEA:Ensembl.
DR   GO; GO:2000773; P:negative regulation of cellular senescence; IEA:Ensembl.
DR   GO; GO:2000352; P:negative regulation of endothelial cell apoptotic process; IEA:Ensembl.
DR   GO; GO:2001240; P:negative regulation of extrinsic apoptotic signaling pathway in absence of ligand; IEA:Ensembl.
DR   GO; GO:0043524; P:negative regulation of neuron apoptotic process; IEA:Ensembl.
DR   GO; GO:0045766; P:positive regulation of angiogenesis; IEA:Ensembl.
DR   GO; GO:0046326; P:positive regulation of D-glucose import; IMP:MGI.
DR   GO; GO:1900087; P:positive regulation of G1/S transition of mitotic cell cycle; IEA:Ensembl.
DR   GO; GO:0042635; P:positive regulation of hair cycle; IMP:BHF-UCL.
DR   GO; GO:1902895; P:positive regulation of miRNA transcription; IEA:Ensembl.
DR   GO; GO:1904751; P:positive regulation of protein localization to nucleolus; IEA:Ensembl.
DR   GO; GO:2000648; P:positive regulation of stem cell proliferation; IMP:BHF-UCL.
DR   GO; GO:1903620; P:positive regulation of transdifferentiation; IEA:Ensembl.
DR   GO; GO:1904754; P:positive regulation of vascular associated smooth muscle cell migration; IEA:Ensembl.
DR   GO; GO:1904707; P:positive regulation of vascular associated smooth muscle cell proliferation; IEA:Ensembl.
DR   GO; GO:0030177; P:positive regulation of Wnt signaling pathway; IGI:BHF-UCL.
DR   GO; GO:0006606; P:protein import into nucleus; IEA:Ensembl.
DR   GO; GO:0031647; P:regulation of protein stability; IEA:Ensembl.
DR   GO; GO:0090399; P:replicative senescence; IEA:Ensembl.
DR   GO; GO:0046686; P:response to cadmium ion; IEA:Ensembl.
DR   GO; GO:0030422; P:siRNA processing; ISS:ComplexPortal.
DR   GO; GO:0140745; P:siRNA transcription; IEA:Ensembl.
DR   GO; GO:0000722; P:telomere maintenance via recombination; NAS:ComplexPortal.
DR   GO; GO:0007004; P:telomere maintenance via telomerase; ISS:UniProtKB.
DR   CDD; cd01648; TERT; 1.
DR   FunFam; 1.10.132.70:FF:000001; Telomerase reverse transcriptase; 1.
DR   FunFam; 1.10.357.90:FF:000001; Telomerase reverse transcriptase; 1.
DR   FunFam; 3.30.70.2630:FF:000001; Telomerase reverse transcriptase; 1.
DR   Gene3D; 1.10.132.70; -; 1.
DR   Gene3D; 1.10.357.90; -; 1.
DR   Gene3D; 3.30.70.2630; -; 1.
DR   InterPro; IPR043502; DNA/RNA_pol_sf.
DR   InterPro; IPR000477; RT_dom.
DR   InterPro; IPR021891; Telomerase_RBD.
DR   InterPro; IPR003545; Telomerase_RT.
DR   InterPro; IPR049139; TERT_C.
DR   PANTHER; PTHR12066; TELOMERASE REVERSE TRANSCRIPTASE; 1.
DR   PANTHER; PTHR12066:SF0; TELOMERASE REVERSE TRANSCRIPTASE; 1.
DR   Pfam; PF00078; RVT_1; 1.
DR   Pfam; PF12009; Telomerase_RBD; 1.
DR   Pfam; PF21399; TERT_C; 1.
DR   PRINTS; PR01365; TELOMERASERT.
DR   SMART; SM00975; Telomerase_RBD; 1.
DR   SUPFAM; SSF56672; DNA/RNA polymerases; 1.
DR   PROSITE; PS50878; RT_POL; 1.
DR   TreeFam; TF329048; -.
PE   1: Evidence at protein level;
KW   Chromosome; Cytoplasm; DNA-binding; Magnesium; Metal-binding;
KW   Nucleotidyltransferase; Nucleus; Phosphoprotein; Reference proteome;
KW   Ribonucleoprotein; RNA-directed DNA polymerase; Telomere; Transferase;
KW   Ubl conjugation.
FT   CHAIN           1..1122
FT                   /note="Telomerase reverse transcriptase"
FT                   /id="PRO_0000054926"
FT   DOMAIN          595..928
FT                   /note="Reverse transcriptase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00405"
FT   REGION          1..239
FT                   /note="RNA-interacting domain 1"
FT                   /evidence="ECO:0000250"
FT   REGION          58..205
FT                   /note="GQ motif"
FT                   /evidence="ECO:0000250"
FT   REGION          137..141
FT                   /note="Required for regulating specificity for telomeric
FT                   DNA and for processivity for primer elongation"
FT                   /evidence="ECO:0000250"
FT   REGION          213..296
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          240..328
FT                   /note="Linker"
FT                   /evidence="ECO:0000250"
FT   REGION          306..528
FT                   /note="Required for oligomerization"
FT                   /evidence="ECO:0000250"
FT   REGION          329..540
FT                   /note="RNA-interacting domain 2"
FT                   /evidence="ECO:0000250"
FT   REGION          381..511
FT                   /note="QFP motif"
FT                   /evidence="ECO:0000250"
FT   REGION          402..422
FT                   /note="CP motif"
FT                   /evidence="ECO:0000250"
FT   REGION          907..921
FT                   /note="Required for oligomerization"
FT                   /evidence="ECO:0000250"
FT   REGION          923..927
FT                   /note="Primer grip sequence"
FT                   /evidence="ECO:0000250"
FT   REGION          929..1122
FT                   /note="CTE"
FT                   /evidence="ECO:0000250"
FT   MOTIF           332..337
FT                   /note="TFLY; involved in RNA binding"
FT                   /evidence="ECO:0000250|UniProtKB:Q4KTA7"
FT   COMPBIAS        284..295
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   BINDING         702
FT                   /ligand="Mg(2+)"
FT                   /ligand_id="ChEBI:CHEBI:18420"
FT                   /ligand_note="catalytic"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00405"
FT   BINDING         861
FT                   /ligand="Mg(2+)"
FT                   /ligand_id="ChEBI:CHEBI:18420"
FT                   /ligand_note="catalytic"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00405"
FT   BINDING         862
FT                   /ligand="Mg(2+)"
FT                   /ligand_id="ChEBI:CHEBI:18420"
FT                   /ligand_note="catalytic"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00405"
FT   SITE            169
FT                   /note="Required for optimal binding of telomeric ssDNA and
FT                   incorporation of nucleotides at the second position of the
FT                   template"
FT                   /evidence="ECO:0000250"
FT   SITE            860
FT                   /note="Required for nucleotide incorporation and primer
FT                   extension rate"
FT                   /evidence="ECO:0000250"
FT   MOD_RES         447
FT                   /note="Phosphoserine; by DYRK2"
FT                   /evidence="ECO:0000250|UniProtKB:O14746"
FT   MOD_RES         697
FT                   /note="Phosphotyrosine; by SRC-type Tyr-kinases"
FT                   /evidence="ECO:0000250|UniProtKB:O14746"
FT   CONFLICT        553
FT                   /note="I -> V (in Ref. 4; AAB84200)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   1122 AA;  127978 MW;  F85266905DD6558C CRC64;
     MTRAPRCPAV RSLLRSRYRE VWPLATFVRR LGPEGRRLVQ PGDPKIYRTL VAQCLVCMHW
     GSQPPPADLS FHQVSSLKEL VARVVQRLCE RNERNVLAFG FELLNEARGG PPMAFTSSVR
     SYLPNTVIET LRVSGAWMLL LSRVGDDLLV YLLAHCALYL LVPPSCAYQV CGSPLYQICA
     TTDIWPSVSA SYRPTRPVGR NFTNLRFLQQ IKSSSRQEAP KPLALPSRGT KRHLSLTSTS
     VPSAKKARCY PVPRVEEGPH RQVLPTPSGK SWVPSPARSP EVPTAEKDLS SKGKVSDLSL
     SGSVCCKHKP SSTSLLSPPR QNAFQLRPFI ETRHFLYSRG DGQERLNPSF LLSNLQPNLT
     GARRLVEIIF LGSRPRTSGP LCRTHRLSRR YWQMRPLFQQ LLVNHAECQY VRLLRSHCRF
     RTANQQVTDA LNTSPPHLMD LLRLHSSPWQ VYGFLRACLC KVVSASLWGT RHNERRFFKN
     LKKFISLGKY GKLSLQELMW KMKVEDCHWL RSSPGKDRVP AAEHRLRERI LATFLFWLMD
     TYVVQLLRSF FYITESTFQK NRLFFYRKSV WSKLQSIGVR QHLERVRLRE LSQEEVRHHQ
     DTWLAMPICR LRFIPKPNGL RPIVNMSYSM GTRALGRRKQ AQHFTQRLKT LFSMLNYERT
     KHPHLMGSSV LGMNDIYRTW RAFVLRVRAL DQTPRMYFVK ADVTGAYDAI PQGKLVEVVA
     NMIRHSESTY CIRQYAVVRR DSQGQVHKSF RRQVTTLSDL QPYMGQFLKH LQDSDASALR
     NSVVIEQSIS MNESSSSLFD FFLHFLRHSV VKIGDRCYTQ CQGIPQGSSL STLLCSLCFG
     DMENKLFAEV QRDGLLLRFV DDFLLVTPHL DQAKTFLSTL VHGVPEYGCM INLQKTVVNF
     PVEPGTLGGA APYQLPAHCL FPWCGLLLDT QTLEVFCDYS GYAQTSIKTS LTFQSVFKAG
     KTMRNKLLSV LRLKCHGLFL DLQVNSLQTV CINIYKIFLL QAYRFHACVI QLPFDQRVRK
     NLTFFLGIIS SQASCCYAIL KVKNPGMTLK ASGSFPPEAA HWLCYQAFLL KLAAHSVIYK
     CLLGPLRTAQ KLLCRKLPEA TMTILKAAAD PALSTDFQTI LD
//
